Alkermes price target raised to $34 from $33 at BofA

BofA raised the firm’s price target on Alkermes (ALKS) to $34 from $33 and keeps a Neutral rating on the shares. The firm, which revised its model to include the recently completed Avadel acquisition, also raised its assumed pricing for Alkermes’ orexin to $175,000 from $130,000, lifting its nominal peak sales estimate to $1.8B from $1.4B.